Document is current
Any future updates will be listed below
-
Authors
Xu, Xiao https://orcid.org/0009-0003-5547-1686
Edmonds, Christopher
Kim, YongJin https://orcid.org/0000-0002-3055-9943
Stokes, Michael https://orcid.org/0000-0002-1822-6214
Stirnadel-Farrant, Heide A.
Kwiatek, Justin
Katial, Rohit
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 16 May 2024
Accepted: 8 August 2024
First Online: 24 October 2024
Declarations
:
: All authors had full control of all primary data and agree to allow the journal to review their data if requested. Xiao Xu is an employee and shareholder of AstraZeneca; Christopher Edmonds is an employee and shareholder of AstraZeneca; YongJin Kim is an employee and shareholder of AstraZeneca and was an employee of Evidera at the time of study conduct; Michael Stokes is an employee of Evidera; Heide A. Stirnadel-Farrant is an employee and shareholder of AstraZeneca; Justin Kwiatek is an employee and shareholder of GSK and was an employee and shareholder of AstraZeneca at the time of study conduct; Rohit Katial is an employee of National Jewish Health, was an employee and shareholder of AstraZeneca at the time of study conduct, and has received honoraria and consulting fees from AstraZeneca. Evidera received research funding/consulting fees from AstraZeneca for the design and implementation of analyses.
: This study used data from Optum’s de-identified Clinformatics<sup>®</sup> Data Mart Database, with permission. The data are compliant with the Health Insurance Portability and Accountability Act; therefore, Institutional Review Board approval was not required.
